The biotechnology stories in 2024 may have been less conspicuous than others this year but the strong investment themes are still there, obesity included. David Pinniger talks through how biotechnology has fared within healthcare’s very strong 2024, the types of company where he is seeing the best opportunities and where investors should be thinking of next.

He also talks through how the Polar Capital Biotechnology Fund is positioned now as well as giving his outlook for the next 12-18 months and beyond.